| Daratumumab, bortezomib, and dexamethasone for multiple myeloma A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ... New England Journal of Medicine 375 (8), 754-766, 2016 | 1660 | 2016 |
| Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America DM Weber, C Chen, R Niesvizky, M Wang, A Belch, EA Stadtmauer, ... New England Journal of Medicine 357 (21), 2133-2142, 2007 | 1615 | 2007 |
| Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans Journal of British Surgery 107 (11), 1440-1449, 2020 | 1145 | 2020 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1007 | 2012 |
| Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma DJ Kuhn, Q Chen, PM Voorhees, JS Strader, KD Shenk, CM Sun, ... Blood, The Journal of the American Society of Hematology 110 (9), 3281-3290, 2007 | 885 | 2007 |
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma DS Siegel, T Martin, M Wang, R Vij, AJ Jakubowiak, S Lonial, S Trudel, ... Blood, The Journal of the American Society of Hematology 120 (14), 2817-2825, 2012 | 808 | 2012 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 JR Mikhael, D Dingli, V Roy, CB Reeder, FK Buadi, SR Hayman, ... Mayo Clinic Proceedings 88 (4), 360-376, 2013 | 693 | 2013 |
| Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions A Chanan-Khan, J Szebeni, S Savay, L Liebes, NM Rafique, CR Alving, ... Annals of Oncology 14 (9), 1430-1437, 2003 | 545 | 2003 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study H Gacaferi, GS Collaborative, COVIDSurg Collaborative Anaesthesia 76 (6), 2021 | 534* | 2021 |
| Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group MA Dimopoulos, E Terpos, A Chanan-Khan, N Leung, H Ludwig, ... Journal of clinical oncology 28 (33), 4976-4984, 2010 | 533 | 2010 |
| Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 M Dimopoulos, R Kyle, JP Fermand, SV Rajkumar, J San Miguel, ... Blood, The Journal of the American Society of Hematology 117 (18), 4701-4705, 2011 | 532 | 2011 |
| Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study A Chanan-Khan, KC Miller, L Musial, D Lawrence, S Padmanabhan, ... Journal of clinical oncology 24 (34), 5343-5349, 2006 | 521 | 2006 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 507* | 2021 |
| Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic … A Chanan-Khan, P Cramer, F Demirkan, G Fraser, RS Silva, S Grosicki, ... The Lancet Oncology 17 (2), 200-211, 2016 | 505 | 2016 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL W Ding, BR LaPlant, TG Call, SA Parikh, JF Leis, R He, TD Shanafelt, ... Blood, The Journal of the American Society of Hematology 129 (26), 3419-3427, 2017 | 420 | 2017 |
| Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group C Fernández de Larrea, RA Kyle, BGM Durie, H Ludwig, S Usmani, ... Leukemia 27 (4), 780-791, 2013 | 410 | 2013 |
| Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial JC Byrd, P Hillmen, P Ghia, AP Kater, A Chanan-Khan, RR Furman, ... Journal of clinical oncology 39 (31), 3441, 2021 | 394 | 2021 |
| Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic … S O'Brien, JO Moore, TE Boyd, LM Larratt, A Skotnicki, B Koziner, ... Journal of Clinical Oncology 25 (9), 1114-1120, 2007 | 373 | 2007 |
| Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study AA Chanan-Khan, JL Kaufman, J Mehta, PG Richardson, KC Miller, ... Blood 109 (6), 2604-2606, 2007 | 344 | 2007 |
